---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-073099"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:53:27.136939+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical announces $30M buyback and China NMPA approval for EVO+ TICL

## Summary
- Authorized $30M share repurchase program, expected to run over six months from cash on hand.
- Company had $222.8M cash and equivalents, no debt as of March 28, 2025; ~49.5M shares outstanding.
- China's NMPA approved EVO+ Toric ICL for myopia correction (-0.5D to -18D, astigmatism ≤6D).
- EVO+ spheric ICL application remains pending with NMPA; Switzerland manufacturing validations ongoing for China supply.

## SEC filing metadata
- accession: 0000950170-25-073099
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000095017025073099/0000950170-25-073099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000095017025073099/staa-20250516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-073099
- JSON: https://secwatch.observer/filing/0000950170-25-073099.json
- Plain text: https://secwatch.observer/filing/0000950170-25-073099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.